55m
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today ...
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company ...
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), "Company"), a ...
Trivy backdoored, FBI buys location data, iOS DarkSword kit, WhatsApp usernames, Langflow RCE, Cisco FMC zero-day & critical ...
On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -- GLIX1 is positioned to potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results